Hims & Hers Prepares Peptide Launch as Investors Temper Near-Term Growth Expectations
What's Happening
Hims & Hers Health is preparing to launch a range of legally available peptide therapies by the end of 2026, expanding beyond its current telehealth offerings. However, despite growing interest in peptide-based wellness treatments, Wall Street analysts believe the new products are unlikely to significantly boost the company's revenue this year.
The company plans to introduce peptides such as NAD+, sermorelin, and glutathione, which are marketed for metabolic support, weight management, recovery, and immune health. Broader expansion into additional peptide therapies will depend on future FDA regulatory decisions regarding compounded peptides.
What Are Peptides?
Peptides are short chains of amino acids that serve as building blocks for proteins and are increasingly being explored for medical and wellness applications.
Some peptides are used or studied for:
- Weight management.
- Muscle recovery.
- Anti-aging therapies.
- Metabolic health.
- Hormone regulation.
- Tissue repair.
While interest has grown rapidly, many peptide therapies remain under FDA review or are not approved for widespread clinical use.
Why Investors Remain Cautious
Although peptides represent a potentially large market, analysts expect only a modest financial contribution in the near term.
Several factors are limiting short-term expectations:
- Many of the initial peptides Hims plans to sell are already legally available through other providers.
- Some of the most anticipated peptide therapies are still awaiting FDA rulemaking.
- Analysts expect demand to build gradually rather than resemble the rapid adoption seen with GLP-1 weight-loss medications.
- Revenue growth from peptides is expected to take several years rather than occur immediately.
Industry estimates place the peptide market between $2.2 billion and $3.3 billion, but most analysts view it as a long-term opportunity rather than a major 2026 growth driver.
Hims' Competitive Position
Despite cautious revenue expectations, Hims & Hers may have several strategic advantages.
The company has:
- Acquired its own peptide manufacturing facility.
- Built an integrated telehealth platform.
- Established a large subscriber base.
- Expanded pharmacy and fulfillment capabilities.
- Invested in AI-powered healthcare services.
These capabilities could allow Hims to scale peptide offerings quickly if FDA regulations become more favorable.
Industry Impact
- Digital Health Companies: The planned launch reflects growing interest in expanding telehealth platforms beyond traditional prescription services into personalized wellness and preventive care.
- Healthcare Providers: As peptide therapies gain attention, providers may see increased patient interest while continuing to monitor evolving clinical evidence and regulatory guidance.
- Pharmaceutical and Compounding Pharmacies: Future FDA decisions could reshape the compounded peptide market and create new commercial opportunities for manufacturers and telehealth companies.
- Investors: Although the peptide market represents a promising long-term opportunity, analysts expect growth to be gradual and dependent on regulatory developments.
Looking Ahead
Hims & Hers plans to launch peptides that are already legally permitted by the end of 2026 while waiting for final FDA guidance on additional compounds currently under review.
Future growth will largely depend on FDA decisions regarding compounded peptides and the company's ability to scale manufacturing and patient adoption over the coming years. Analysts believe the peptide business could eventually become a significant revenue contributor, but not in the immediate future.
Why This Matters
The announcement highlights how telehealth companies are broadening their services beyond traditional virtual care into wellness, preventive health, and personalized medicine.
While peptide therapies remain an emerging market, regulatory decisions and clinical evidence will play a critical role in determining how quickly they become part of mainstream healthcare.
Key Takeaways
- Hims & Hers plans to launch several legally available peptide therapies by the end of 2026.
- Analysts expect limited revenue impact this year despite strong long-term market potential.
- Future growth depends on FDA decisions regarding additional compounded peptides.
- Hims' manufacturing capabilities and telehealth platform may provide a competitive advantage.
- The peptide market represents a long-term expansion opportunity for digital health companies.
What This Means for Healthcare Marketers
Hims & Hers' peptide strategy highlights growing investment in telehealth, personalized medicine, wellness therapies, and preventive healthcare. Digital health companies, compounding pharmacies, pharmaceutical manufacturers, and healthcare technology providers continue exploring new treatment categories that combine virtual care with personalized therapies. For healthcare marketers, organizations involved in telemedicine, wellness, pharmacy services, and personalized healthcare represent high-intent opportunities for provider education, patient engagement, product commercialization, and strategic growth.